The hemostatic profile of recombinant activated factor VII. Can low concentrations stop bleeding in off-label indications?

Thrombosis Journal

Volumn 8, Issue , 2010, Pages

  Altman, Raul ^a   Scazziota, Alejandra ^a   de Lourdes Herrera, Maria ^a   Gonzalez, Claudio D ^b  

^a Centro de Trombosis de Buenos Aires   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; THROMBOPLASTIN;

AREA UNDER THE CURVE; ARTICLE; AUTOANALYSIS; BLEEDING DISORDER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; MONOTHERAPY; NORMAL HUMAN; OFF LABEL DRUG USE; THROMBOCYTE ACTIVATION; THROMBOCYTE POOR PLASMA; THROMBOCYTE RICH PLASMA; VOLUNTEER;

EID: 77951789526     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-8-8     Document Type: Article

References (32)

1. Hedner U. Potential role of rFVIIa in prophylaxis in severe haemophilia patients with inhibitors. J Thromb Haemost 2006, 4:2498-500. 10.1111/j.1538-7836.2006.02166.x, 16907841.
2. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006, 124:747-57. 10.1016/j.jbiotec.2006.03.042, 16697480.
3. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005, 33:883-90. 10.1097/01.CCM.0000159087.85970.38, 15818119.
4. Romagnoli S, Bevilacqua S, Gelsomino S, Romagnoli S, Bevilacqua S, Gelsomino S, Pradella S, Ghilli L, Rostagno C, Gensini GF, Sorbara C. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg 2006, 102:1320-6. 10.1213/01.ane.0000209023.96418.e5, 16632803.
5. Stein DM, Dutton RP, Hess JR, Scalea TM. Low-dose recombinant factor VIIa for trauma patients with coagulopathy. Injury 2008, 39:1054-61. 10.1016/j.injury.2008.03.032, 18656871.
6. Altman R, Scazziota A, de Lourdes Herrera M, Gonzalez C. Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation. J Thromb Haemost 2006, 4:2022-7. 10.1111/j.1538-7836.2006.02088.x, 16961610.
7. Hemker HC, Giesen P, Aldieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Beguin S. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002, 32:249-53. 10.1159/000073575, 13679651.
8. Abshire T, Kenet G. Safety update on the use of recombinant VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 2008, 14:898-902. 10.1111/j.1365-2516.2008.01829.x, 18684126.
9. Hedner U. Mechanism of action of factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost 2006, 32(Suppl 1):77-85. 10.1055/s-2006-939557, 16673269.
10. Hedner U. Mechanism of action of recombinant activated factor VII: an update. Semin Hematol 2006, 43(1 Suppl 1):S105-7. 10.1053/j.seminhematol.2005.11.025, 16427375.
11. Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005, 131:645-55. 10.1111/j.1365-2141.2005.05820.x, 16351642.
12. Aggarwal A, Malkovska V, Catlett JP, Alcorn K. Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage. Thromb J 2004, 2:9. 10.1186/1477-9560-2-9, 535534, 15530167.
13. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T, . Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005, 352:777-85. 10.1056/NEJMoa042991, 15728810, Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators.
14. Bowman LJ, Uber WE, Stroud MR, Christiansen LR, Lazarchick J, Crumbley AJ, Kratz JM, Toole JM, Crawford FA, Ikonomidis JS. Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery. Ann ThoracSurg 2008, 85:1669-76.
15. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factorVIIa. JAMA 2006, 295:293-8. 10.1001/jama.295.3.293, 16418464.
16. Pichon N, Bellec F, Sekkal S, Marsaud JP, Laskar M, François B, Vignon P. Fatal thrombotic event after infusion of recombinant activated factor VII after cardiac surgery. J Thorac Cardiovasc Surg 2008, 136:220-1. 10.1016/j.jtcvs.2007.10.084, 18603082.
17. Hsia CC, Chin-Yee IH, McAlister VC. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg 2008, 248:61-8. 10.1097/SLA.0b013e318176c4ec, 18580208.
18. Yilmaz D, Karapinar B, Balkan C, Akisü M, Kavakli K. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder. Pediatr Hematol Oncol 2008, 25:301-11. 10.1080/08880010802016904, 18484474.
19. Alten JA, Benner K, Green K, Toole B, Tofil NM, Winkler MK. Pediatric off-label use of recombinant factor VIIa. Pediatrics 2009, 123:1066-72. 10.1542/peds.2008-1685, 19255041.
20. Howes JL, Smith RS, Helmer SD, Taylor SM. Complications of recombinant activated human coagulation factor VII. Am J Surg 2009, 198:895-9. 10.1016/j.amjsurg.2009.05.026, 19969148.
21. Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Brun NC, Broderick JP. Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke 2010, 41:48-53. 10.1161/STROKEAHA.109.561712, 19959538.
22. Altman R, Scazziota AS, Herrera M de L, Gonzalez C. Thrombin generation by activated factor VII on platelet activated by different agonists. Extending the cell-based model of hemostasis. Thromb J 2006, 4:5. 10.1186/1477-9560-4-5, 1459108, 16630353.
23. Lisman T, Adelmeijer J, Cauwenberghs S, van Pampus ECM, Heemskerk JWM, de Groot PG. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost 2005, 3:742-51. 10.1111/j.1538-7836.2005.01227.x, 15842358.
24. Levi M, ten Cate H. Disseminated intravascularcoagulation. N Engl J Med 1999, 341:586-92. 10.1056/NEJM199908193410807, 10451465.
25. Morel O, Jesel L, Freyssinet JM, F Toti F. Elevated levels of procoagulant microparticles in a patient with myocardial infarction, antiphospholipid antibodies and multifocal cardiac thrombosis. Thromb J 2005, 3:15. 10.1186/1477-9560-3-15, 1266401, 16219103.
26. Franchini M, Giuseppe Lippi G, Manzato F. Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thromb J 2006, 4:4. 10.1186/1477-9560-4-4, 1402263, 16504043.
27. Hedner U. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost 2008, 100:557-62.
28. Masud F, Bostan F, Chi E, Pass SE, Samir H, Stuebing K, Liebl MG. Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: a retrospective analysis of dosing, efficacy, and safetyoutcomes. J Cardiothorac Vasc Anesth 2009, 23:28-33. 10.1053/j.jvca.2008.08.003, 18948033.
29. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, Büller HR, Levi M. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003, 361:201-5. 10.1016/S0140-6736(03)12268-4, 12547542.
30. Johnson SJ, Ross MB, Moores KG. Dosing factor VIIa (recombinant) in nonhemophiliac patients with bleeding after cardiac surgery. Am J Health Syst Pharm 2007, 64:1808-12. 10.2146/ajhp060398, 17724361.
31. Hsia CC, Chin-Yee IH, McAlister VC. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg 2008, 248:61-8. 10.1097/SLA.0b013e318176c4ec, 18580208.
32. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK, Badimon JJ, O'Connor WN. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004, 110:2032-8. 10.1161/01.CIR.0000143233.87854.23, 15451780.